Press Releases BioRestorative Therapies, Inc.

Equities

BRTX

US0906556065

Real-time Estimate Cboe BZX Other stock markets 19:40:28 13/05/2024 BST			5-day change	1st Jan Change
1.33 ^USD	-2.92%		-10.81%	-24.13%

05-08	BioRestorative Therapies, Inc. Enhances Preclinical Metabolic Program with A Novel Exosome-Based Biologic Targeting Obesity	CI
04-30	BioRestorative Therapies, Inc. Announces Transformative Commercial Agreement with Cartessa Aesthetics, LLC	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity	05-08	AQ
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024	04-30	AQ
BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology	04-30	AQ
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment	04-16	AQ
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease	04-08	AQ
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants	04-03	AQ
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K	04-01	AQ
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference	03-11	AQ
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market	02-06	AQ
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease	02-05	AQ
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting	02-01	AQ
BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program	12-12	AQ
BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City	09/10/23	AQ
BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics	12/09/23	AQ
BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease	11/09/23	AQ
BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease	08/09/23	AQ
BioRestorative Therapies Announces $2.1 Million Registered Direct Offering	11/07/23	AQ
BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes	27/06/23	AQ
BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET	16/06/23	AQ
BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease	12/06/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioRestorative Therapies, Inc.

Equities

BRTX

US0906556065

Press Releases

Filters